IFNAR1 and infection: We performed a more detailed characterization of the model using the following parameters: administration of 0.1 mg per mouse of anti-IFNAR1 mAb, followed 48 h later by infection with CHIKV, MAYV, or ONNV at a dose of 105 TCID50.